MedImmune/AstraZeneca: EVT770

The loss of insulin producing beta cells is tightly linked to the development of diabetes. EVT770 is a secreted molecule that has been identified in a screen for potential beta cell regeneration targets. It has been demonstrated that the factor can stimulate beta cell proliferation and neogenesis in vitro and in vivo.

In December 2010, Evotec entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca) to develop EVT770 in the field of diabetes.

In January 2013, Evotec announced that it has expanded the scope of its collaboration with MedImmune after hitting a key milestone. The milestone triggers a commercial license granted to MedImmune and an extension of the diabetes and beta cell regeneration collaboration to the end of 2013.

15 December 2010
Metabolic disease alliance with MedImmune

07 January 2013
Evotec expands collaboration with MedImmune, receives milestone payment

May 20, 2013
03:45 PM CET